StageAcq - P2P | Acquired
About Constellation Pharmaceuticals
Constellation Pharmaceuticals (NASDAQ: CNST) is a biopharmaceutical company dedicated to the development of therapeutics in the emerging field of Epigenetics, a new field of science involving selective regulators that are critical to controlling gene expression. Constellation Pharmaceuticals is initially focused on oncology but per the company, it believes its technology platform will likely be applicable to other therapeutic areas, including autoimmune, inflammatory, and neurological diseases.
Missing: Constellation Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Constellation Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Constellation Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Constellation Pharmaceuticals is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Constellation Pharmaceuticals Patents
Constellation Pharmaceuticals has filed 77 patents.
The 3 most popular patent topics include:
- Transcription factors
Transcription factors, Epigenetics, Human proteins, Experimental cancer drugs, Proteins
Transcription factors, Epigenetics, Human proteins, Experimental cancer drugs, Proteins
Latest Constellation Pharmaceuticals News
Dec 6, 2022
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net sales MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered into a global licensing agreement with Novartis to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. This program was added to MorphoSys’ research portfolio following its acquisition of Constellation Pharmaceuticals, Inc. “We are pleased that our trusted and long-standing collaborator Novartis will continue to drive this program forward. Novartis has strong medicinal chemistry, oncology development and translational research capabilities to realize the full potential of this novel cancer target,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. “At MorphoSys, we will continue to focus our resources on driving our late- and mid-stage oncology pipeline forward, which has the potential to enhance the standard and quality of care in difficult-to-treat and debilitating types of blood cancers.” Under the terms of the agreement, Novartis will assume full responsibility for all subsequent research, development and commercialization activities for the program. As part of the agreement, MorphoSys receives an immediate upfront payment of $23 million. On achievement of development, regulatory and commercial milestones, MorphoSys will be eligible to receive milestone payments from Novartis in addition to mid-single- to low-double-digit royalties on program net sales. About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at morphosys.com and follow us on Twitter and LinkedIn . Forward Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact:
Constellation Pharmaceuticals Frequently Asked Questions (FAQ)
When was Constellation Pharmaceuticals founded?
Constellation Pharmaceuticals was founded in 2008.
Where is Constellation Pharmaceuticals's headquarters?
Constellation Pharmaceuticals's headquarters is located at 215 First Street, Cambridge.
What is Constellation Pharmaceuticals's latest funding round?
Constellation Pharmaceuticals's latest funding round is Acq - P2P.
How much did Constellation Pharmaceuticals raise?
Constellation Pharmaceuticals raised a total of $244.6M.
Who are the investors of Constellation Pharmaceuticals?
Investors of Constellation Pharmaceuticals include MorphoSys, Venrock, Third Rock Ventures, The Column Group, SR One and 17 more.
Who are Constellation Pharmaceuticals's competitors?
Competitors of Constellation Pharmaceuticals include Cevec Pharmaceuticals, InflaRx, Acetylon Pharmaceuticals, Kolltan Pharmaceuticals, Auspex Pharmaceuticals and 15 more.
Compare Constellation Pharmaceuticals to Competitors
KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.
Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).
Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.
Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Tolera Therapeutics is developing targeted therapies for immune suppression and immune tolerance, designed for use in organ transplant surgeries and other medical settings requiring safer, more targeted immune modulation. The goal is to provide improved induction therapy with a better safety profile than current treatment options. The company's technology, which stems from organ transplant research done at the Cleveland Clinic, has been undergoing clinical research and has been tested in humans. The regulatory pathway is expected to bring a product to market in 2012.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.